Compare · MBX vs NVO
MBX vs NVO
Side-by-side comparison of MBX Biosciences Inc. (MBX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MBX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 133.1x MBX ($1.44B).
- Over the past year, MBX is up 151.0% and NVO is down 45.2% - MBX leads by 196.2 points.
- MBX has been more active in the news (10 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 12 for MBX).
- Company
- MBX Biosciences Inc.
- Novo Nordisk A/S
- Price
- $28.56-5.62%
- $41.34-3.73%
- Market cap
- $1.44B
- $191.82B
- 1M return
- -18.14%
- -9.75%
- 1Y return
- +150.97%
- -45.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 10
- 8
- Recent ratings
- 12
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MBX
- SEC Form 4 filed by Director Mathers Edward T
- SEC Form 4 filed by Director Pescovitz Ora H.
- SEC Form 4 filed by Director Heron Patrick J
- SEC Form 4 filed by Director Stelzer Laurie
- SEC Form 4 filed by Director Hoerter Steven L.
- SEC Form 4 filed by Director Ryder Steven
- SEC Form 4 filed by Director Aynechi Tiba
- MBX Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
- MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care